Source: Eur Respir J , 49 (4)  1601102; DOI: 10.1183/13993003.01102-2016
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Xin Xu, Tarek Abdalla, Preston E. Bratcher, Patricia L. Jackson, Gina Sabbatini, J. Michael Wells, Xiang-Yang Lou, Rebecca Quinn, J. Edwin Blalock, J. P. Clancy, Amit Gaggar. Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur Respir J , 49 (4)  1601102; DOI: 10.1183/13993003.01102-2016

Member's Comments

No comment yet.

Related content which might interest you: Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Predictive factors for severe pulmonary exacerbations in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 715s Year: 2006 Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Assessing response to treatment of exacerbations of bronchiectasis in adults Source: Eur Respir J 2009; 33: 312-318 Year: 2009 Etiology and clinical outcome of pediatric non-cystic fibrosis bronchiectasis Source: Annual Congress 2010 - Paediatric epidemiology: infection, prematurity and congenital abnormalities Year: 2010 Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019 Year: 2019 Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function Source: International Congress 2016 – Cystic fibrosis: monitoring and management Year: 2016 The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art Year: 2008 Incidence and resource utilisation of pulmonary exacerbations in patients with cystic fibrosis in the UK Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Exacerbations in non cystic fibrosis bronchiectasis: clinical features and investigations Source: Annual Congress 2009 - Bacterial infections of upper and lower respiratory tract in childhood Year: 2009 Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Factors associated with recurrence of severe exacerbations in Non-cystic fibrosis bronchiectasis in developping countries. Source: International Congress 2019 – Clinical problems Year: 2019 Lung clearance index improves with treatment of an exacerbation in cystic fibrosis Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage Year: 2007 Frequent outpatient exacerbations of non cystic fibrosis bronchiectasis leads to impaired health related quality of life Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021 Year: 2021 Inflammatory markers can predict pulmonary exacerbations of cystic fibrosis Source: International Congress 2017 – Cystic fibrosis: monitoring and biomarkers Year: 2017